Promoter methylation analysis of CDH1 and p14ARF genes in patients with urothelial bladder cancer

Urothelial bladder cancer arises from the accumulation of multiple epigenetic and genetic changes. We aimed to investigate the specificity and sensitivity of gene-specific promoter methylation of and genes in the early diagnosis of bladder cancer and compare those with other diagnostic tests in our...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2018-01, Vol.11, p.4189-4196
Main Authors: Bayramov, Bayram, Gunes, Sezgin, Buyukalpelli, Recep, Aydın, Oğuz, Henkel, Ralf
Format: Article
Language:English
Subjects:
Biomarkers
Bladder cancer
Cancer diagnosis
Cancer genetics
Cancer patients
Cancer research
Cell adhesion & migration
Cell cycle
Cellular biology
Deoxyribonucleic acid
DNA
DNA methylation
Epigenetic inheritance
Epigenetics
Gene expression
Genes
Genetic aspects
Genetic testing
Genomics
Medical research
Medicine
Methylation
Mutation
Original Research
Ovarian cancer
Polymerase chain reaction
Studies
Tumors
Urine
Urology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Urothelial bladder cancer arises from the accumulation of multiple epigenetic and genetic changes. We aimed to investigate the specificity and sensitivity of gene-specific promoter methylation of and genes in the early diagnosis of bladder cancer and compare those with other diagnostic tests in our population. In the current study, 65 patients with urothelial bladder cancer and 35 controls without any history of cancer were recruited. Methylation profiles of and genes from tumor and urine samples were determined by methylation-specific polymerase chain reaction method. Methylation of and genes in tumor samples was 95.4% and 78.5%, respectively. The methylation frequencies were found to be 68.8% for gene and 72.9% for gene in urine samples. Sensitivities of , and urine cytology were found to be 67.4%, 72.1% and 34.9%, respectively, while their specificities were 93.9%, 63.6% and 93.9%, respectively. Aberrant promoter methylation of and genes can be used to detect urothelial bladder cancer. In low-grade tumors, when compared with urine cytology, combined methylation analysis of and genes may not increase the sensitivity to identify malignant cells in urine samples.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S158259